VYNE Therapeutics (VYNE) Revenue & Revenue Breakdown
VYNE Therapeutics Revenue Highlights
Latest Revenue (Y)
$424.00K
Latest Revenue (Q)
$98.00K
Main Segment (Y)
Royalty
VYNE Therapeutics Revenue by Period
VYNE Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $424.00K | -11.11% |
| 2022-12-31 | $477.00K | -96.77% |
| 2021-12-31 | $14.76M | -29.71% |
| 2020-12-31 | $20.99M | 4638.83% |
| 2019-12-31 | $443.00K | -95.84% |
| 2018-12-31 | $10.64M | 132.21% |
| 2017-12-31 | $4.58M | 579.82% |
| 2016-12-31 | $674.00K | 100.00% |
| 2015-12-31 | - | - |
VYNE Therapeutics generated $424.00K in revenue during NA 2023, up -11.11% compared to the previous quarter, and up 3.98% compared to the same period a year ago.
VYNE Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $98.00K | 28.95% |
| 2023-12-31 | $76.00K | -33.33% |
| 2023-09-30 | $114.00K | -15.56% |
| 2023-06-30 | $135.00K | 36.36% |
| 2023-03-31 | $99.00K | 1550.00% |
| 2022-12-31 | $6.00K | -96.41% |
| 2022-09-30 | $167.00K | 32.54% |
| 2022-06-30 | $126.00K | -29.21% |
| 2022-03-31 | $178.00K | -92.23% |
| 2021-12-31 | $2.29M | -43.91% |
| 2021-09-30 | $4.09M | -4.04% |
| 2021-06-30 | $4.26M | 3.37% |
| 2021-03-31 | $4.12M | -3.90% |
| 2020-12-31 | $4.29M | 31.11% |
| 2020-09-30 | $3.27M | -72.03% |
| 2020-06-30 | $11.69M | 567.89% |
| 2020-03-31 | $1.75M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $-10.64M | 100.00% |
| 2018-09-30 | - | -100.00% |
| 2018-06-30 | $10.14M | 1940.85% |
| 2018-03-31 | $497.00K | -82.09% |
| 2017-12-31 | $2.77M | 205.28% |
| 2017-09-30 | $909.00K | 102.45% |
| 2017-06-30 | $449.00K | - |
| 2017-03-31 | $449.00K | -0.22% |
| 2016-12-31 | $450.00K | - |
VYNE Therapeutics generated $98.00K in revenue during Q1 2024, up 28.95% compared to the previous quarter, and up 1633.33% compared to the same period a year ago.
VYNE Therapeutics Revenue Breakdown
VYNE Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|
| Royalty | $477.00K | $931.00K | $791.00K |
| Product | - | $13.82M | $10.20M |
| License | - | - | $10.00M |
| Product and Service, Other | - | - | - |
VYNE Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 22: Royalty (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $100.00K | $6.00K | $167.00K | $178.00K | $273.00K | $133.00K | $295.00K | $230.00K | $180.00K | $406.00K | $205.00K | - |
| Product | - | - | - | - | $2.02M | $3.95M | $3.96M | $3.89M | $4.11M | $2.86M | $1.48M | $1.75M |
| License | - | - | - | - | - | - | - | - | - | $10.00M | - | - |
VYNE Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 23: Royalty (100.00%).
VYNE Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $100.00K | $6.00K | $167.00K | $178.00K | $273.00K | $133.00K | $295.00K | $230.00K | $180.00K | $406.00K | $205.00K | - |
| Product | - | - | - | - | $2.02M | $3.95M | $3.96M | $3.89M | $4.11M | $2.86M | $1.48M | $1.75M |
| License | - | - | - | - | - | - | - | - | - | $10.00M | - | - |
VYNE Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Royalty (100.00%).
VYNE Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VCYT | Veracyte | $361.05M | $96.84M |
| CDTX | Cidara Therapeutics | $63.91M | $8.46M |
| PULM | Pulmatrix | $7.30M | $1.55M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| HSTO | Histogen | $3.77M | $5.00K |
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| CBIO | Gyre Therapeutics | $794.00K | - |
| BCEL | Atreca | $770.00K | $80.00K |
| LGVN | Longeveron | $709.00K | $548.00K |
| UNCY | Unicycive Therapeutics | $675.00K | - |
| VCNX | Vaccinex | $570.00K | $232.00K |
| VYNE | VYNE Therapeutics | $424.00K | $98.00K |
| MGTA | Dianthus Therapeutics | $314.00K | $72.00K |
| ZURA | Zura Bio | - | - |
| REVB | Revelation Biosciences | - | - |
| AKTX | Akari Therapeutics | - | - |
| FWBI | Entero Therapeutics | - | - |
| GOVX | GeoVax Labs | - | - |
| AXLA | Axcella Health | - | - |
| PHIO | Phio Pharmaceuticals | - | - |
| ZVSA | ZyVersa Therapeutics | - | - |
| RNAZ | TransCode Therapeutics | - | - |
| SLRX | Salarius Pharmaceuticals | - | - |
VYNE Revenue FAQ
What is VYNE Therapeutics’s yearly revenue?
VYNE Therapeutics's yearly revenue for 2023 was $424K, representing a decrease of -11.11% compared to 2022. The company's yearly revenue for 2022 was $477K, representing a decrease of -96.77% compared to 2021. VYNE's yearly revenue for 2021 was $14.76M, representing a decrease of -29.71% compared to 2020.
What is VYNE Therapeutics’s quarterly revenue?
VYNE Therapeutics's quarterly revenue for Q1 2024 was $98K, a 28.95% increase from the previous quarter (Q4 2023), and a -1.01% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $76K, a -33.33% decrease from the previous quarter (Q3 2023), and a 1166.67% increase year-over-year (Q4 2022). VYNE's quarterly revenue for Q3 2023 was $114K, a -15.56% decrease from the previous quarter (Q2 2023), and a -31.74% decrease year-over-year (Q3 2022).
What is VYNE Therapeutics’s revenue growth rate?
VYNE Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -97.13%, and for the last 5 years (2019-2023) was -4.29%.
What are VYNE Therapeutics’s revenue streams?
VYNE Therapeutics's revenue streams in c 22 are Royalty
What is VYNE Therapeutics’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of VYNE Therapeutics was Royalty. This segment made a revenue of $477K, representing 100.00% of the company's total revenue.